In vitro tests to evaluate immunotoxicity: A preliminary study

Toxicology

Volumn 229, Issue 1-2, 2007, Pages 11-22

  Carfi', M ^a,d   Gennari, A ^a   Malerba, I ^a   Corsini, E ^b   Pallardy, M ^c   Pieters, R ^d   Van Loveren, H ^e   Vohr, H W ^f   Hartung, T ^a   Gribaldo, L ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b Laboratory of Toxicology   (Italy)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UTRECHT UNIVERSITY   (Netherlands)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^f BAYER PHARMA AG   (Germany)

Author keywords

Benzo(a)pyrene; Cyclosporin A; Furosemide; Tributyltin chloride (TBTC); Urethane; Verapamil

Indexed keywords

BENZO[A]PYRENE; CYCLOSPORIN A; CYTOKINE; FUROSEMIDE; MITOGENIC AGENT; TRIBUTYLTIN; URETHAN; VERAPAMIL;

ANIMAL CELL; ARTICLE; BONE MARROW TOXICITY; CLONOGENESIS; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DATA BASE; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; IN VITRO STUDY; LITERATURE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; ANTIGENS, CD3; BENZO(A)PYRENE; CELL PROLIFERATION; CELL SURVIVAL; CYCLOSPORINE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FUROSEMIDE; HUMANS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; PHYTOHEMAGGLUTININS; RATS; REPRODUCIBILITY OF RESULTS; SPLEEN; T-LYMPHOCYTES; TOXICITY TESTS; TRIALKYLTIN COMPOUNDS; URETHANE; VERAPAMIL;

ANIMALIA; MURINAE; RODENTIA;

EID: 33845347862     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2006.09.003     Document Type: Article

References (26)

1. Balls M., Goldberg A.M., Fentem J.H., Broadhead C.L., Burch R.L., Festing M.F.W., Frazier J.M., Hendriksen C.F.M., Jennings M., Van der Kamp M.D.O., Morton D.B., Rowan A.N., Russell C., Russell W.M.S., Spielmann H., Stephens M.L., Stokes W.S., Straughan D.W., Yager J.D., Zurlo J., and Van Zutphen B.F.M. The three Rs: the way forward. ECVAM Workshop Report 11. ATLA 23 (1995) 838-866
2. Birx D.L., Berger M., and Fleisher T.A. The interference of T cell activation by calcium channel blocking age. J. Immunol. 133 6 (1984) 2904-2909
3. Chow F.-S., and Jusko J.W. Immunosuppressive interactions among calcium channel antagonists and selected corticosteroids and macrolides using human whole blood lymphocytes. Drug Metabol. Pharmacokinet. 19 6 (2004) 413-421
4. COM, 2003. 644: http://europa.eu.int/eur-lex/en/com/pdf/2003/com2003_0644en.html.
5. Dean J.H. Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. Toxicology 119 1 (1997) 95-101
6. Gennari A., Ban M., Braun A., Casati S., Corsini E., Dastych J., Descotes J., Hartung T., Hooghe-Peters R., House R., Pallardy M., Pieters R., Reid L., Tryphonas H., Tschirhart E., Tuschl H., Vandebriel R., and Gribaldo L. The use of in vitro system for evaluating immunotoxicity: the report and recommendations of an ECVAM workshop. J. Immunotoxicol. 2 (2005) 61-83
7. Genshow E., Spielmann H., Scholz G., Seiler A., Brown N., Piersma A., Brady M., Clemann N., Huuskonen H., Paillard F., Bremer S., and Becker K. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. Alternatives Lab. Anim. 30 (2002) 151-176
8. Hartung T., Bremer S., Casati S., Coecke S., Corvi R., Fortaner S., Gribaldo L., Halder M., Hoffmann S., Janusch Roi A., Prieto P., Sabbioni E., Scott L., Worth A., and Zuang V. A modular approach to the ECVAM principles on test validity. ATLA 32 (2004) 467-472
9. HSDB: Hazardous Substances Data Base, 2000. National Library of Medicine. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB.
10. IARC, 1983. 32, 225.
11. Janeway C., Travers P., Walport M., and Capra J. Immunobiology: the Immune System in Health and Disease (1999), Garland Publishers, New York, NY
12. Kim S., Lish J.W., Stai Eric L., Lochmiller R.L., Rafferty D.P., and Qualls C.W. Evaluation of myelotoxicity in cotton rats (Sigmodon hispidus) exposed to environmental contaminants. II. Myelotoxicity associated with petroleum industrial wastes. J. Toxicol. Environ. Health Part A 62 2 (2001) 97-105
13. Kimura K., Kobayashi K., Naito H., Suzuki Y., and Sugita-Konishi Y. Effect of lactational exposure to tributyltin chloride on innate immunodefenses in the F1 generation in mice. Biosci. Biotechnol. Biochem. 69 6 (2005) 1104-1110
14. Kirchner H., Kleinicke C., and Digel W. A whole blood technique for testing production of human interferon by leukocytes. J. Immunol. Meth. 48 (1982) 213-219
15. Langezaal I., Coecke S., and Hartung T. Whole blood cytokine response as a measure of immunotoxicity. Toxicol. In Vitro 15 4-5 (2001) 313-318
16. Lebrec H., Roger R., Blot C., Burleson G.R., Bohuon C., and Pallardy M. Immunotoxicological investigation using pharmaceutical drugs. In vitro evaluation of immune effects using rodent or human immune cells. Toxicology 96 2 (1995) 147-156
17. Luster M.I., Hong H.L., Boorman G.A., Clark G., Hayes H.T., Greenlee W.F., Dold K., and Tucker A.N. Acute myelotoxic responses in mice exposed to 2,3,7,8-tetrachlorodibenzo p-dioxin (TCDD). Toxicol. Appl. Pharmacol. 81 (1985) 156-165
18. Martindale, 2002a. "The complete drug reference", 'Eds 33'. Pharmaceutical Press, London, pp. 893-896.
19. Martindale, 2002b. "The complete drug reference", 'Eds 33'. Pharmaceutical Press, London, pp. 518-524.
20. Pessina A., Albella B., Bueren J., Brantom P., Casati S., Gribaldo L., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Sibiril Y., Schoeters G., and Van Den Heuvel R. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol. In Vitro 15 (2001) 729-740
21. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Schoeters G., Sibiril Y., Van Den Heuvel R., and Gribaldo L. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 75 (2003) 355-367
22. Reed L.J., and Muench H.A. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (1938) 493-497
23. Sigal N.H., Dumont F., Durette P., Siekierka J.J., Peterson L., Rich D.H., Dunlap B.E., Staruch M.J., Melino M.R., Koprak S.L., Williams D., Witzel B., and Pisano J.M. J. Exp. Med. 173 (1991) 619-628
24. Snodin D.J. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development?. Regul. Toxicol. Pharmacol. 40 (2004) 336-355
25. Snoeij N.J., Penninks A.H., and Seinen W. Biological activity of organotin compounds-an overview. Environ. Res. 44 2 (1987) 335-353
26. Wagner W., Walczak-Drzewiecka A., Ślusarczyk A., Biecek P., Rychlewski L., and Dastych J. Fluorescent cell chip a new in vitro approach for immunotoxicity screening. Toxicol. Lett. 162 (2006) 55-70